Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

Yale scientists uncover common mechanism that promotes autoimmune diseases and blood cancers

In a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL).

19 Apr 2021

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.

17 Apr 2021

New recipients for the 2021 NCCN Foundation Young Investigator Awards announced

The National Comprehensive Cancer Network and the NCCN Foundation today announced six new recipients for the 2021 NCCN Foundation Young Investigator Awards Program.

15 Apr 2021

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine.

18 Feb 2021

If I have cancer, dementia or MS, should i get the covid vaccine?

As public demand grows for limited supplies of covid-19 vaccines, questions remain about the vaccines' appropriateness for older adults with various illnesses.

27 Jan 2021

Infusion of convalescent blood plasma benefits patient with severe COVID-19

A 72-year-old woman was hospitalized with severe COVID-19 disease, 33 days after the onset of symptoms.

22 Jan 2021

MDC researchers develop a potent weapon against lymphomas

MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults.

11 Jan 2021

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.

7 Dec 2020

Grants give military veterans better access to cancer clinical trials

SWOG Cancer Research Network and its charity, The Hope Foundation for Cancer Research, announce the award of two grants designed to give military veterans better access to cancer clinical trials.

11 Nov 2020

Commonly prescribed anti-depressant may halt the growth of childhood sarcoma

A new study has found that a commonly prescribed anti-depressant may halt growth of a type of cancer known as childhood sarcoma, at least in mice and laboratory cell experiments.

6 Nov 2020

Case study reports prolonged infectious SARS-CoV-2 shedding from an asymptomatic leukemia patient

The majority of people infected with SARS-CoV-2 appear to actively shed infectious virus for about 8 days, but there is a wide range of variability from person to person.

4 Nov 2020

Researchers are developing a new class of compounds against various cancers

Researchers at The Wistar Institute and collaborators from the University of Notre Dame are developing anticancer compounds targeting a pathway of the endoplasmic reticulum (ER) stress response implicated in the development of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and lymphoma.

14 Oct 2020

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

The U.S. Food and Drug Administration has granted Fast Track designation to a novel "switchable" CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process.

1 Oct 2020

Researchers unravel new mechanism of cell survival in chronic lymphocytic leukemia

Researchers at The Wistar Institute unraveled a mechanism employed by chronic lymphocytic leukemia (CLL) cells for their survival.

30 Sep 2020

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.

10 Aug 2020

Clinical study evaluates potential of oral cancer drug to reduce respiratory symptoms of COVID-19

Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Ohio State University Wexner Medical Center are conducting a new clinical trial to determine if an oral cancer drug called ibrutinib can also help patients with cancer or other immunocompromised conditions recover from COVID-19.

29 Jul 2020

Dual inhibitor therapy may be safer for CLL patients, Moffitt study shows

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. One in four new leukemia cases are CLL.

14 Jul 2020

New NCCN guidelines explain how to recognize and manage immunotherapy-related side effects

The National Comprehensive Cancer Network today announced the completion of the new NCCN Guidelines for Patients®: Immunotherapy Side Effects series, with the publication of a book focused on chimeric antigen receptor (CAR) T-cell therapy. This closely follows the publication of a separate book on immune checkpoint inhibitors, both created with support from the NCCN Foundation®.

1 Jul 2020

New drug can prevent life-threatening anaphylaxis, shows study

For someone with a food or drug allergy, the risk of life-threatening anaphylactic shock lurks around every corner. A new Northwestern Medicine study shows there might be a pill that can be taken proactively to prevent mild to life-threatening anaphylaxis, no matter the cause.

3 Jun 2020